evade – COOPER GENERAL NEWS

A medical worker injects a man with a dose of the COVID-19 vaccine at a hospital in Accra, capital of Ghana, May 19, 2021.

Seth | Xinhua News Agency | Getty Images

Top health officials in Europe and Africa said Wednesday they are worried about the potential emergence of new Covid variants that could render current vaccines useless.

Dr. John Nkengasong, director of Africa’s Centres for Disease Control and Prevention, said he is “very concerned” about the emergence of a vaccine-resistant variant as the Delta variant first detected in India continues to spread around the world. Studies have shown that current vaccines work against the new variant, although not as well as they do against the original wild type virus.

“It is increasingly concerning that this pandemic will be driven by the cycle of occurrence and reoccurrence of different variants,” Nkengasong said at The Wall Street Journal’s Health Tech conference. “The speed at which these viruses overtake the existing viruses is amazing.”

The Delta variant was first identified by scientists in October has since spread to more than 62 countries, dominating the U.K. and now responsible for more new infections in the country than the Alpha variant — which was first detected in the U.K.

Dr. Sharon Peacock, executive chair of Covid-19 Genomics U.K. Consortium, said the Delta variant is about 40% to 50% more transmissible than the Alpha variant, formerly called B.1.1.7, a strain that emerged from the U.K. last fall and was more contagious than the original virus.

“So, given that level of transmissibility, I would anticipate that (the Delta variant) would’ve actually spread around the world,” she said at the conference. Peacock added the Delta variant is already present in most U.S. states, but the spread is at an early stage.

White House senior medical advisor, Dr. Anthony Fauci told reporters yesterday that the U.S. needs to vaccinate more people before the Delta variant takes hold in the country.

The Alpha variant is currently the dominant variant in the U.S., but the Delta variant could soon take over like it did in the U.K. “We cannot let that happen in the United States,” Fauci said yesterday.

“I would be concerned … that this will be something that will be able to out-compete other circulating variants in the way that we’ve observed in the United Kingdom,” Peacock said. She also said that variants are more likely to emerge in partially vaccinated areas. Some states in the U.S. have vaccination rates higher than 70%, while others lag behind at 40%.

Scientists in the U.S. are currently sequencing just 1.6% of new infections, Peacocks said. She and Nkengasong agreed that increased genomic surveillance is an important way to track the spread of new variants before they take hold.

Dave Ricks, chairman and CEO of Eli Lilly, told CNBC on Tuesday that he expected the company’s Covid-19 antibody drug to be effective against the variant of coronavirus found in the UK

However, he said the exposure observed in South Africa is likely to be more of a challenge.

“The South African variant … is cause for concern. It has more dramatic mutations to the spike protein that these antibody drugs target,” Ricks told Squawk Box. “In theory, it could evade our drugs.”

Eli Lilly’s antibody drug was approved for emergency use by the US Food and Drug Administration in November. The drug is aimed at people recently diagnosed with Covid-19 in hopes of preventing the need for hospitalization. Regeneron’s Covid-19 antibody treatment, which President Donald Trump received after contracting the disease, has also received limited approval from the FDA.

According to Ricks, Eli Lilly wants to work with the FDA to quickly test different versions of antibodies to see if they are against virus variants like the one in South Africa.

“We actually have a large library of these antibodies now that are pre-clinical,” said Ricks. “We could think of a very expedited way to study them in a month or two and then approve their use. That seems like a smart thing because this virus is mutating.”

Discovery of variants

Coronavirus variants originally found in the UK and South Africa have received significant attention in recent weeks. They are believed to be more transmissible – but not more deadly – than previous tribes. Even so, a more contagious virus that leads to more infections could continue to weigh on healthcare systems and lead to more deaths.

The discovery of these mutations also coincides with the introduction of Covid-19 vaccines from drug companies such as Pfizer and BioNTech, as well as Moderna. It has led to some questions about whether the vaccines – along with treatments for the disease – would keep their effectiveness.

In a CNBC interview on Monday, Dr. Ugur Sahin, CEO of BioNTech, confident that his vaccine, manufactured in partnership with Pfizer, will work against the strains of the virus found in the UK and South Africa.

Daniel O’Day, CEO of Gilead Sciences, told CNBC it was testing its remdesivir treatment against these new strains, but said Monday the antiviral drug would likely be effective. Antiviral drugs like remdesivir try to prevent the virus from replicating. In contrast, antibodies like Eli Lillys bind to the virus present in the body and try to neutralize it.

There have been no confirmed cases of the variant, which was first discovered in South Africa in America, but according to the Wall Street Journal, it was discovered in countries like Japan, South Korea, and Switzerland. According to the Centers for Disease Control and Prevention, there have been around 70 confirmed cases of the coronavirus variant in the US that were originally found in the UK.

“It seems clear that Lilly’s single antibody, and likely Regeneron’s cocktail, will stop this as well as the normal variant,” said Ricks of the UK-affiliated tribe. “We haven’t done a clinical study of this effect, but we do have pre-clinical data that strongly suggests that it won’t be a problem.”

Use of antibody therapies

After the FDA approved emergency use for their antibody therapies to Eli Lilly and later Regeneron, problems arose with actually delivering the drug, which requires an intravenous infusion, to Covid patients. In mid-December, CNBC reported that between 5% and 20% of the doses delivered had been administered.

That number is “climbing” now, Ricks said on Monday. He pointed to Alabama as a state where the antibodies are widespread. Alabama “basically runs out and refills every week,” he said.

“There are quite a few” from state to state, Ricks admitted. “We want all states to learn from these practices and really be able to use this medicine, as the benefit is that patients, especially seniors, are kept out of the hospital. We know if you are a senior and have Covid-19 and end up in a hospital hospital bed, the prospects are not good. “